Qingdao Vland Biotech Co Ltd
Qingdao Vland Biotech INC. engages in the research and development, production, and sale of enzyme preparations, microecological preparations, and animal health products in China and internationally. It offers feed, industrial, and food enzymes; and probiotics, including aquaculture premixes, health products, and animal and plant probiotics. The company also offers animal vaccines and biological … Read more
Qingdao Vland Biotech Co Ltd (603739) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.14 Billion CNY
Based on the latest financial reports, Qingdao Vland Biotech Co Ltd (603739) has total liabilities worth CN¥1.14 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Qingdao Vland Biotech Co Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Qingdao Vland Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Qingdao Vland Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Qingdao Vland Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stockmann Oyj Series B
LSE:0MW2
|
UK | €1.17 Billion |
|
CHRCF
PINK:CHRCF
|
USA | $66.01 Million |
|
Concord International Securities Co Ltd
TWO:5864
|
Taiwan | NT$3.09 Billion |
|
Ta Ann Holdings Bhd
KLSE:5012
|
Malaysia | RM691.13 Million |
|
Sunteck Realty Limited
NSE:SUNTECK
|
India | ₹53.82 Billion |
|
Anhui Huangshan Capsule Co Ltd
SHE:002817
|
China | CN¥156.93 Million |
|
VITZROCELL Co.Ltd
KQ:082920
|
Korea | ₩36.50 Billion |
|
CPH Chemie und Papier Holding
SW:CPHN
|
Switzerland | CHF166.65 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Qingdao Vland Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Qingdao Vland Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Qingdao Vland Biotech Co Ltd (2014–2024)
The table below shows the annual total liabilities of Qingdao Vland Biotech Co Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.11 Billion | -8.08% |
| 2023-12-31 | CN¥1.21 Billion | +43.05% |
| 2022-12-31 | CN¥844.93 Million | +57.59% |
| 2021-12-31 | CN¥536.18 Million | +59.47% |
| 2020-12-31 | CN¥336.22 Million | +35.03% |
| 2019-12-31 | CN¥248.99 Million | -20.69% |
| 2018-12-31 | CN¥313.94 Million | +7.88% |
| 2017-12-31 | CN¥291.02 Million | +7.80% |
| 2016-12-31 | CN¥269.96 Million | -10.69% |
| 2015-12-31 | CN¥302.27 Million | -8.00% |
| 2014-12-31 | CN¥328.53 Million | -- |